United States

Pfizer Buying Medivation in Deal Valued at About $14 Billion

87876199
Photo by Spencer Platt/Getty Images

Pfizer will pay about $14 billion in cash for the cancer drug company Medivation, a deal that will add the pricey late-stage prostate cancer treatment Xtandi to its oncology portfolio.

The New York drugmaker said Monday that it will pay $81.50 per Medivation share. That's a 21 percent premium to the San Francisco biotech's Friday closing price of $67.19.

Medivation Inc. and the Japanese drugmaker Astellas Pharma jointly market Xtandi, with Astellas selling the drug outside the U.S.

U.S. & World

Stories that affect your life across the U.S. and around the world.

Lawyer: Trump Offered Assange a Pardon If He Cleared Russia of DNC Hack

Ryan Newman Released From Hospital After Daytona 500 Crash

Xtandi drew attention earlier this year from the public interest group Knowledge Economy International, which petitioned the National Institutes of Health to reduce the $129,000-a year list price for the advanced prostate cancer treatment. The government declined.

Pfizer Inc. said Medivation also has promising pipeline of cancer drugs in late-stage clinical development. That includes the potential breast cancer treatment talazoparib and a potential lymphoma drug.

The boards of both companies have approved the deal, which is targeted to close in the third of fourth quarter.

The deal comes about three months after Medivation rejected a $9.3 billion takeover bid from the French drugmaker Sanofi, saying that offer, worth $52.50 per share, undervalued the company.

Shares of Medivation Inc. soared more than 19 percent before the opening bell Monday.

Copyright AP - Associated Press
Contact Us